Insmed has launched a Phase 1 clinical trial testing INS1202, an experimental gene therapy for ALS. INS1202 is designed to reduce levels of the toxic SOD1 protein implicated in some ALS cases, ...

The Muscular Dystrophy Association (MDA) concluded its 2026 MDA Clinical & Scientific Conference yesterday, convening over 2,400 attendees from 40 countries to help shape the future of neuromuscular ...

Data from BridgeBio Pharma’s Phase 3 FORTIFY study show that BBP-418 significantly increases levels of a key disease biomarker that helps stabilize muscles in patients with limb-girdle muscular ...

Data presented at the 2026 Muscular Dystrophy Association meeting could have readthroughs to companies developing therapies for spinal muscular atrophy, Duchenne muscular dystrophy and Becker muscular ...

Musculoskeletal disorders are a primary cause of disability worldwide, especially in aging societies like Japan. As individuals age, reductions in muscle mass and physical activity weaken the body's ...

BridgeBio Pharma Inc. BBIO on Wednesday announced a recent presentation of interim results from its Phase 3 FORTIFY trial for BBP-418, a treatment for limb-girdle muscular dystrophy type 2I/R9.

Anna Gragert (she/her/hers) was previously the lifestyle editor at HelloGiggles, deputy editor at So Yummy and senior lifestyle editor at Hunker. Over the past 10+ years, Anna has also written for the ...

Up to three years of Evrysdi treatment appears safe and may help presymptomatic children with SMA reach and maintain key milestones.

SMA newborn screening may help infants start treatment sooner, which researchers say could support better motor development outcomes.